PĚČ, Ondřej, Petr BOB and Jiří RABOCH. Dissociation in schizophrenia and borderline personality disorder. Neuropsychiatric Disease and Treatment. New Zealand: Dove Medical Press, 2014, vol. 10, March, p. 487-491. ISSN 1176-6328. Available from: https://dx.doi.org/10.2147/NDT.S57627.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Dissociation in schizophrenia and borderline personality disorder
Authors PĚČ, Ondřej (203 Czech Republic), Petr BOB (203 Czech Republic, guarantor, belonging to the institution) and Jiří RABOCH (203 Czech Republic).
Edition Neuropsychiatric Disease and Treatment, New Zealand, Dove Medical Press, 2014, 1176-6328.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher New Zealand
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.154 in 2013
RIV identification code RIV/00216224:14740/14:00079327
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.2147/NDT.S57627
UT WoS 000332838500001
Keywords in English dissociation; stress-related symptoms; schizophrenia; borderline personality disorder; antipsychotic medication
Tags kontrola MP, MP, rivok
Tags International impact, Reviewed
Changed by Changed by: Martina Prášilová, učo 342282. Changed: 3/3/2015 09:53.
Abstract
Background: Dissociation likely plays a key role in schizophrenia and borderline personality disorder (BPD), although empirical studies that compare specific manifestations of these symptoms in schizophrenia and BPD are rare. In this context, the purpose of this study was to compare the occurrence of dissociative and other psychopathological symptoms in these disorders, and to assess the possible influence of antipsychotic medication on the dissociative symptoms. Methods: We assessed 31 patients with schizophrenia and 36 patients with BPD. Dissociative symptoms were measured by the Dissociative Experiences Scale (DES), symptoms related to stress and traumatic experiences were assessed using the Trauma Symptom Checklist-40 (TSC-40), and other psychopathological symptoms were measured with the Health of the Nation Outcome Scales (HoNOS). We also assessed actual daily doses of antipsychotic medication in chlorpromazine equivalents in all participants. Results: The results show that symptoms of traumatic stress measured by the TSC-40 had significantly higher scores in the BPD group. The data also show that dissociative symptoms (DES) were significantly correlated with symptoms of traumatic stress (TSC-40) and with symptoms assessed by the HoNOS. Remarkably significant correlations were found between levels of antipsychotic medication and the DES and between antipsychotic medication and the depersonalization/derealization component of the DES in BPD patients. Conclusion: The results support an important role of dissociative processes in schizophrenia and BPD and suggest a significant relationship between manifestations of dissociative symptoms in BPD and antipsychotic medication.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
PrintDisplayed: 26/4/2024 10:31